Jason M. Broderick

The FDA has granted a full approval to tarlatamab-dlle for extensive-stage small cell lung cancer.

The FDA has approved sevabertinib for HER2-mutant nonsquamous non–small cell lung cancer.

At the 43rd Annual CFS meeting, John Allan, MD, highlighted ongoing efforts to advance the treatment paradigm for chronic lymphocytic leukemia.

The FDA has approved daratumumab and hyaluronidase for the treatment of patients with high-risk smoldering multiple myeloma.

Jonathan Strosberg, MD, details findings with 212Pb-DOTAMTATE in patients with gastroenteropancreatic neuroendocrine tumors from the ALPHAMEDIX-02 trial.

A groundbreaking study reveals 212Pb-DOTAMTATE's promising efficacy and safety in treating advanced gastroenteropancreatic neuroendocrine tumors.

Raludotatug deruxtecan (R-DXd) demonstrates significant antitumor activity and manageable safety in platinum-resistant ovarian cancer, paving the way for further studies.

Trastuzumab rezetecan significantly improves progression-free survival in HER2-positive breast cancer, outperforming standard treatments in a pivotal trial.

The ALPHAMEDIX-02 trial showed promising results for 212Pb-DOTAMTATE in previously treated gastroenteropancreatic neuroendocrine tumors.

The SKYSCRAPER-03 trial showed that consolidation tiragolumab plus atezolizumab does not improve progression-free survival in advanced lung cancer compared to durvalumab.

A phase 1/2 trial shows saruparib combined with ARPI offers high response rates and manageable safety in metastatic prostate cancer patients.

A new drug application for Dasynoc was not approved for patients with chronic myeloid leukemia and acute lymphoblastic leukemia.

Replimune navigates FDA challenges for RP1, an innovative melanoma treatment, while emphasizing the urgent need for effective therapies in advanced cases.

A new study reveals that combining vitrectomy and silicone oil with plaque brachytherapy may enhance survival rates in uveal melanoma patients.

Neoadjuvant darovasertib showed promising tumor shrinkage in patients with uveal melanoma.

With pegtarazimod and belumosudil advancing through the global pipeline, options are expanding for patients with GVHD worldwide.

High Ki-67 expression predicts poorer survival in patients with acral melanoma, a rare subtype in which Ki-67's predictive value had not been established.

Patient dosing has continued to successfully escalate in an early-phase trial of a novel FSHR-targeting CAR T-cell therapy in ovarian cancer.

A significant number of patients with ovarian cancer miss preventive salpingectomy opportunities during unrelated surgeries.

Pembrolizumab showed strong anti-tumor activity in patients with unresectable desmoplastic melanoma.

A phase 3 trial showed that alpelisib plus olaparib did not reduce the risk of progression or death in relapsed/refractory ovarian cancer.

A promising allogeneic CAR T therapy has shown the potential to succeed in ovarian cancer where standard CAR-T treatments have failed.

The results support the potential for treatment de-escalation after hysterectomy for women with early-stage, intermediate-risk cervical cancer.

The CAR-T treatment GLPG5101 received the FDA's RMAT designation by showing promising efficacy with rapid delivery and low toxicity in mantle cell lymphoma.

The NCCN added critical guidance on Lambert-Eaton myasthenic syndrome to its recommendation for the diagnosis and treatment of small cell lung cancer.

Despite its increased use, immunoglobulin replacement therapy does not lower the risk of serious infection in patients with chronic lymphocytic leukemia.

The FDA has cleared investigational new drug applications for ZW251 and RV‑01, advancing novel treatments for solid tumors in first-in-human trials.

The CDK2 inhibitor INCB123667 showed positive efficacy and safety signals in platinum-resistant/refractory ovarian cancer.

New research suggests that certain patients with low-risk thyroid cancer can safely forgo postoperative radioiodine ablation without compromising long-term outcomes.

A study reveals that venetoclax consolidation after BTKi therapy is effective for chronic lymphocytic leukemia, offering promising outcomes for patients.